CSIMarket
 


Gt Biopharma Inc   (GTBP)
Other Ticker:  
 

Gt Biopharma Inc 's Quick Ratio

GTBP's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 3.2 above Gt Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 255 other companies have achieved higher Quick Ratio than Gt Biopharma Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 473 to 833.

Explain Quick Ratio?
How much Cash & cash equivalents GTBPīs has?
What are GTBPīs Current Liabilities?


GTBP Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -0.54 % -45.15 % -57.11 % 25.91 % 53.39 %
Y / Y Cash & cash equivalent Change -22.95 % -24.24 % -25.58 % -53.78 % -47.39 %
Quick Ratio MRQ 3.2 3.81 4.88 3.34 4.14
GTBP's Total Ranking # 833 # 473 # 667 # 1069 # 911
Seq. Current Liabilities Change 5.82 % 15.87 % -17.46 % -1.73 % -41.64 %
Seq. Cash & cash equivalent Change -10.9 % -9.68 % 20.54 % -20.57 % -12.4 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 256
Healthcare Sector # 440
Overall Market # 833


Quick Ratio Statistics
High Average Low
12.06 1.37 0
(Jun 30 2021)   (Jun 30 2014)




Financial Statements
Gt Biopharma Inc 's Current Liabilities $ 5 Millions Visit GTBP's Balance sheet
Gt Biopharma Inc 's Cash & cash equivalent $ 16 Millions Visit GTBP's Balance sheet
Source of GTBP's Sales Visit GTBP's Sales by Geography


Cumulative Gt Biopharma Inc 's Quick Ratio

GTBP's Quick Ratio for the trailling 12 Months

GTBP Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -0.54 % -45.15 % -57.11 % 25.91 % 53.39 %
Y / Y Cash & cash equivalent TTM Growth -22.95 % -24.24 % -25.58 % -53.78 % -47.39 %
Quick Ratio TTM 3.76 4.01 3.57 3.13 3.95
Total Ranking TTM # 696 # 3471 # 4251 # 4413 # 321
Seq. Current Liabilities TTM Growth 5.82 % 15.87 % -17.46 % -1.73 % -41.64 %
Seq. Cash & cash equivalent TTM Growth -10.9 % -9.68 % 20.54 % -20.57 % -12.4 %


On the trailing twelve months basis In spite of the year on year decrease in GTBP's Current Liabilities to $5.00 millions, cumulative Quick Ratio to 3.76 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 267 other companies have achieved higher Quick Ratio than Gt Biopharma Inc . While Quick Ratio overall ranking has improved so far to 696, from total ranking during the twelve months ending second quarter 2023 at 3471.

Explain Quick Ratio?
How much Cash & cash equivalents GTBPīs has?
What are GTBPīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 268
Healthcare Sector # 457
Within the Market # 696


trailing twelve months Quick Ratio Statistics
High Average Low
6.37 1.24 0
(Mar 31 2022)   (Mar 31 2016)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Point Biopharma Global Inc   8.77 $ 339.163  Millions$ 38.666  Millions
Zentalis Pharmaceuticals Inc   8.77 $ 516.637  Millions$ 58.918  Millions
Bullfrog Ai Holdings Inc   8.64 $ 3.856  Millions$ 0.446  Millions
Spruce Biosciences Inc   8.59 $ 108.032  Millions$ 12.572  Millions
Cerevel Therapeutics Holdings Inc   8.59 $ 676.882  Millions$ 78.838  Millions
Tff Pharmaceuticals Inc   8.52 $ 9.726  Millions$ 1.142  Millions
Rapt Therapeutics Inc   8.46 $ 184.777  Millions$ 21.849  Millions
Scpharmaceuticals Inc   8.43 $ 90.198  Millions$ 10.703  Millions
Sol gel Technologies Ltd   8.40 $ 37.996  Millions$ 4.522  Millions
Shuttle Pharmaceuticals Holdings Inc   8.40 $ 6.807  Millions$ 0.810  Millions
An2 Therapeutics Inc   8.35 $ 123.818  Millions$ 14.836  Millions
Longboard Pharmaceuticals Inc   8.35 $ 56.016  Millions$ 6.712  Millions
Tango Therapeutics Inc   8.29 $ 359.880  Millions$ 43.416  Millions
Allakos Inc   8.27 $ 193.908  Millions$ 23.450  Millions
Rani Therapeutics Holdings Inc   8.24 $ 60.526  Millions$ 7.345  Millions
Oncolytics Biotech Inc   8.24 $ 26.743  Millions$ 3.246  Millions
Bicycle Therapeutics Plc  8.20 $ 572.086  Millions$ 69.736  Millions
Cassava Sciences Inc  8.17 $ 142.350  Millions$ 17.414  Millions
Oncternal Therapeutics Inc   8.06 $ 40.305  Millions$ 5.001  Millions
Centessa Pharmaceuticals Plc  8.05 $ 281.341  Millions$ 34.954  Millions
Cogent Biosciences Inc   8.04 $ 279.041  Millions$ 34.719  Millions
Vascular Biogenics Ltd   7.98 $ 20.768  Millions$ 2.601  Millions
Amylyx Pharmaceuticals Inc   7.78 $ 355.045  Millions$ 45.617  Millions
Gossamer Bio Inc   7.77 $ 328.888  Millions$ 42.316  Millions
Glycomimetics Inc   7.74 $ 49.460  Millions$ 6.391  Millions
Leap Therapeutics inc   7.57 $ 80.743  Millions$ 10.669  Millions
Hoth Therapeutics Inc   7.51 $ 11.853  Millions$ 1.579  Millions
Applied Molecular Transport Inc   7.47 $ 18.103  Millions$ 2.422  Millions
Aileron Therapeutics Inc   7.43 $ 12.069  Millions$ 1.624  Millions
Ngm Biopharmaceuticals Inc   7.43 $ 166.045  Millions$ 22.345  Millions

Date modified: 2023-11-29T20:12:54+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com